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ABSTRACT 
Alpha-tocopherol is one the most abundant and biologically active isoforms of vitamin E. This compound is a 
potent antioxidant and one of most studied isoforms of vitamin E. Vitamin D3 (cholecalciferol) is an important 
nutrient for calcium homeostasis and bone health, that has also been recognized as a potent modulator of the 
immune response. Methicillin-resistant Staphylococcus aureus (MRSA) is the most important causative agent of 
both nosocomial and community-acquired infections. The aim of this study was to evaluate the inhibitory effect 
of alpha-tocopherol and cholecalciferol on both S. aureus and multidrug resistant S. aureus efflux pumps. The 
RN4220 strain has the plasmid pUL5054 that is the carrier of gene that encodes the macrolide resistance protein 
(an efflux pump) MsrA; the IS-58 strain possesses the TetK tetracycline efflux protein in its genome and the 
1199B strain resists to hydrophilic fluoroquinolones via a NorA-mediated mechanism. The antibacterial activity 
was evaluated by determining the Minimal Inhibitory Concentration (MIC) and a possible inhibition of efflux 
pumps was associated to a reduction of the MIC. In this work we observed that in the presence of the treatments 
there was a decrease in the MIC for the RN4220 and IS-58 strains, suggesting that the substances presented an 
inhibitory effect on the efflux pumps of these strains. Significant efforts have been done to identify efflux pump 
inhibitors (EPIs) from natural sources and, therefore, the antibacterial properties of cholecalciferol and alpha-
tocopherol might be attributed to a direct effect on the bacterial cell depending on their amphipathic structure. 
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INTRODUCTION 
Alpha-tocopherol is one of the most 
abundant and biologically active isoforms of 
vitamin E. This compound is a potent 
antioxidant and one of most studied isoforms 
of vitamin E (Márquez et al., 2002; Catania 
et al., 2009).Vitamin E is a liposoluble 
substance that is able to slow aging and 
protect organisms from non-transmissible 
chronic diseases, such as Parkinson’s, 
Alzheimer’s, infectious and rheumatic states, 
cancer and cardiovascular diseases (Catania 
et al., 2009; Batista et al., 2007; Berg, 2010). 
Recent findings demonstrated that vitamin E 
is able to inhibit the growth of malignant 
cells (Sampaio and Almeida, 2009) and 
modulate cell signaling and gene 
transcription (Batista et al., 2007). Vitamin E 
(Alpha-tocopherol) is naturally present in 
many products of both plant and animal 
origin, such as: vegetable oils, wheat germ, 
oily seeds, dark-red vegetables, egg yolk and 
in the liver.  
Vitamin D3, or cholecalciferol, and 
vitamin D2, or ergocalciferol, are two 
different forms of vitamin D obtained by 
humans. Ergocalciferol is produced by many 
plants, yeasts and fungi when they are 
exposed to UVB radiation and 
cholecalciferol is synthesized in the skin by 
exposure to UVB radiation (Bikle, 2009). 
Vitamin D has been recognized as a potent 
modulator of the immune response and as an 
important nutrient for calcium homeostasis 
(Holick, 2004; Heaney, 2005; Miller and 
Gallo, 2010). The main circulating form of 
this vitamin in the organism is the 25-
hydroxyvitamin D (25[OH]D) (calcidiol), 
which requires activation by the renal 1 α-
hydroxylase to form the metabolically active 
1,25-dihydroxvitamin D (1,25[OH]2D) 
(calcitriol) (DeLuca, 2004). 
Liposoluble compounds are known as 
modifiers of the bacterial cell membrane 
permeability (Pretto et al., 2004; Nicolson et 
al., 1999). Therefore, alpha-tocopherol and 
cholecalciferol due to their liposolubility 
might increase the permeability of the 
bacterial cell membrane to various 
substances, including antibiotics (Andrade et 
al., 2014). 
Beyond the intrinsic resistance properties 
to certain antibiotics, bacteria can also 
acquire resistance to antibiotics via 
horizontal gene transfer and mutations in 
chromosomal genes. The intrinsic resistance 
of a bacterial species to a particular antibiotic 
is its ability to resist to the action of this 
antibiotic as a result of inherent structural or 
functional characteristics, resulting on 
antibiotic inactivation (Blair et al., 2015). 
Accordingly, there has been increasing 
concern about bacterial resistance to 
antibiotics, specially because of the 
availability and inappropriate use of these 
drugs (Neuhauser et al., 2003; Sahm et al., 
2001). In fact, numerous bacterial strains, 
especially the methicillin-resistant variety, 
rapidly became resistant to antibacterial 
agents after the introduction of antibiotics for 
treatment of serious infections caused by S. 
aureus (Harnett et al., 1991; Mesak and 
Davies, 2009). 
Methicillin-resistant Staphylococcus 
aureus (MRSA) is the most important 
causative agent of both community-acquired 
and nosocomial bacterial infections. S. 
aureus cause these infections through 
various virulence factors (Costa et al., 2011; 
Havaei et al., 2010). MRSA strains present 
resistance to many antibacterial agents, 
limiting the treatment of many patients 
infected with these bacteria (Kurlenda and 
Grinholc, 2012). There are three different 
mechanisms of antibiotic resistance to S. 
aureus: inactivation of the antibiotic by 
hydrolysis or chemical modification; 
modification of the antibiotic target by 
genetic mutation or post-translational 
mechanisms; and reduction of the 
intracellular concentrations of the antibiotic 
as a result of deficient penetration into the 
bacterium or antibiotic efflux by active 
mechanisms (Blair et al., 2015). 
The active efflux of substances that 
inhibit bacterial growth such as toxic 
compounds and antibiotics, in S. aureus, is 
mediated by integral membrane transporters, 
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known as drug efflux pumps (Levy, 1992). 
There are several categories of active drug 
efflux pumps that transport drugs against 
their concentration gradients across the 
membrane (Levy, 1992). In the S. aureus 
species, the following efflux proteins are 
found: QacA (Small multidrug resistance 
protein from the SMR family) (Paulsen et 
al., 1996; Saier et al., 1994), Smr (SMR 
family) (Grinius et al., 1992), Tetk (Major 
facilitator superfamily from the MFS 
family), NorA (MFS family) (Yoshida et al., 
1990) and MsrA (MFS family) (Reynolds et 
al., 2003). 
Several studies have demonstrated the 
development of antibiotic resistance in 
pathogenic bacteria during the course of 
antibiotic treatment which involved efflux 
pumps (Levy, 2005; Neu, 1992; Levy, 2002). 
Therefore, it is hypothesized that the 
antibiotic therapy can be effective if: (i) 
efflux pumps are inhibited, (ii) the 
expression of efflux pumps is 
downregulated, or (iii) the antibiotics are 
redesigned, so that they are no longer 
suitable to efflux substrates and thus, their 
clinical efficacy is restored (Kourtesi et al., 
2013). 
The aim of this study was to evaluate the 
inhibitory effect of alpha-tocopherol and 
cholecalciferol on the Staphylococcus aureus 
efflux pumps. 
 
MATERIALS AND METHODS 
Bacterial strains  
The following strains of S. aureus were 
used: RN4220, which has the plasmid 
pUL5054 that is the carrier of gene that 
encodes the macrolide resistance protein (an 
efflux pump) MsrA; IS-58, which possesses 
the TetK tetracycline efflux protein in its 
genome and 1199B, which resists to 
hydrophilic fluoroquinolones via a NorA-
mediated mechanism. All strains used in this 
work were kindly provided by Prof. S. 
Gibbons (University of London). These 
strains were maintained in blood agar base 
culture medium slants (Laboratorios Difco 
Ltda., Brazil) and, before the assays, the cells 
were kept grown overnight at 37 °C in Heart 
Infusion Agar culture medium slants (HIA, 
Difco) during 24 hours. 
 
Drugs  
The antibiotics were dissolved in 
dimethyl sulfoxide (DMSO) and then, 
diluted in sterile water to the concentration 
of 1024 μg/mL). Erythromycin, norfloxacin 
and tetracycline were used as antibiotics. 
Alpha-tocopherol and cholecalciferol were 
obtained from Sigma Chemical Co. (St. 
Louis, USA). Stock solutions of the vitamins 
were prepared in 1 mL of DMSO to obtain 
the concentration of 200 mg/ml and then, 
this solutions were diluted to 1024 µg/mL in 
distilled water to reduce the DMSO toxicity. 
 
Antibacterial activity test by Minimal  
Inhibitory Concentration (MIC) 
The MICs of alpha-tocopherol and 
cholecalciferol were determined in a 
microdilution assay utilizing an inoculum of 
100 μL of each strain suspended in saline 
solution at 0.5 of the McFarland scale, was 
added in brain heart infusion (BHI) in 
Eppendorfs. Then, each sample was 
transferred to 96-well microtiter plates and 
serial dilutions of each substance were 
performed with concentrations ranging from 
0.5 to 512 µg/mL. The plates were incubated 
at 37 °C during 24 h, and bacterial growth 
was determined using the sodium Resazurin 
colorimetric method. The MIC was defined 
as the lowest concentration in which no 
bacterial growth was observed, according to 
CLSI (2013). The antibacterial assays were 
performed in triplicate and the results were 
expressed as average of the replicates. 
 
Evaluation of the inhibition of efflux 
pumps by reduction of MIC 
To analyze whether alpha-tocopherol and 
cholecalciferol might affect the efflux pump 
activity, we evaluated the potential of these 
substances to decrease the MIC of the 
antibiotics. The inhibition of the efflux pump 
was evaluated using sub-inhibitory 
concentrations of alpha-tocopherol and 
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cholecalciferol (MIC/8). A 100 μL sample of 
a solution containing inoculums, suspended 
in saline solution at 0.5 of the McFarland 
scale was added in brain heart infusion 
(BHI) in Eppendorfs. Then, each sample was 
transferred to 96-well microtiter plates and 
serial dilutions of each substance were per-
formed with concentrations ranging from 0.5 
to 512 µg/mL. The plates were incubated at 
37 °C during 24 h, and bacterial growth was 
determined using the sodium Resazurin col-
orimetric method. The antibiotic MICs were 
used as controls. The antibacterial assays 
were performed in triplicate and the results 
were expressed as average of the replicates. 
 
Statistical analysis  
All experiments were made in triplicate. 
The data were analyzed using two-way 
ANOVA and the Tukey´s post test using 
GraphPad Prism software 5.0 (GraphPad, 
San Diego, CA). The values are expressed as 
geometric means and the differences with p ˂ 
0.05 were considered significant. 
 
RESULTS AND DISCUSSION 
Cholecalciferal and alpha-tocopherol 
presented a MIC ≥ 1024 µg/mL and, as such, 
they do not exhibit clinically relevant anti-
bacterial activity. However, when associated 
with antibiotics against resistant strains car-
rying efflux pumps, cholecalciferol reduced 
the MIC values of the antibiotics (Figures 1-
4). 
Substances that reverse bacterial re-
sistance when associated with antibiotics by 
reducing their MIC are defined as "modifiers 
of the antibiotic activity", which can alter the 
bacterial susceptibility to antibiotics by in-
hibiting microbial efflux pumps (Costa et al., 
2008). Thus, if a substance causes a reduc-
tion in the MIC ≥ 3 dilutions when combined 
with the inhibitor, this is an indicative that 
this substance affects the bacterial resistance 
by inhibiting the efflux pump activity (Da-
vies and Wright, 1997). 
 
Figure 1: MIC of Tetracycline alone and in asso-
ciation with the standard vitamins against the 
strain S. aureus IS-58, expressing the efflux sys-
tem TetK. One Way ANOVA, followed by the test 
Tukey. a4p < 0,0001 vs Tetracycline; ns - not sig-
nificant 
 
Figure 2: MIC of Erythromycin alone and in as-
sociation with the standard vitamins against the 
strain S. aureus RN4220, expressing the efflux 
system TetK. One Way ANOVA, followed by the 
test Tukey. a4p < 0,0001 vs Erythromycin; ns - 
not significant 
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Figure 3: MIC of Norfloxacin alone and in asso-
ciation with the standard vitamins against the 
strain S. aureus 1199B, expressing the efflux 
system TetK. One Way ANOVA, followed by the 
test Tukey. ns - not significant 
 
 
Figure 4: MIC of Norfloxacin alone and in asso-
ciation with the standard vitamins against the 
strain S. aureus 1199B wild, expressing the ef-
flux system TetK. One Way ANOVA, followed by 
the test Tukey. a4p < 0,0001 vs Norfloxacin; b4p < 
0,0001 vs Norfloxacin. 
 
 
The association of antibiotics with lipo-
soluble vitamins is an interesting alternative 
to enhance the antimicrobial efficacy of 
these drugs, because these vitamins are 
commonly present in the human feed and 
present no significant toxicity when used at 
low concentrations (DiPalma and Ritchie, 
1977). This is the first study demonstrating 
the effect of cholecalciferol and alpha-
tocopherol as inhibitors of antibiotic efflux 
systems. Andrade et al. (2014) were the first 
researchers to demonstrate the antibiotic 
modulatory activity against aminoglycosides 
using a multidrug resistant (MDR) strain of 
Staphylococcus aureus, although several re-
ports previously demonstrated the antibiotic 
modulator effect of many non-polar com-
pounds against MDR strains. 
Falcão-Silva et al. (2009) demonstrated 
that the amphipathic kaempferol glycoside 
tiliroside increased the action antibiotics by 
reducing the concentration needed to inhibit 
the growth of the RN4220 and IS-58 strains. 
One of the factors that might be associated to 
this inhibition is the lipophilicity of the fla-
von moiety of tiliroside. Lipophilicity is a 
common feature of several efflux pump in-
hibitors (EPIs), and this feature, as pointed 
out by Gibbons (2004), is probably im-
portant for EPIs solubility in the bacterial 
membrane and binding to the efflux pump or 
efflux pump substrates. Thus, the lipophilici-
ty of a given compound may be determinant 
on inhibiting the efflux pump in Gram-
positive multi-resistant bacteria (Stavri et al., 
2007). Accordingly, several reports have 
demonstrated that lipophilic compounds act 
as inhibitors of drug efflux pumps in cancer 
cells (Werle, 2008). Finally, other amphi-
pathic compounds such as piperidine alka-
loids (Gibbons, 2005), acylated oligosaccha-
rides from the orizabin series (Pereda-
Miranda et al., 2006) and from the muru-
coidin series, stoloniferin I (Chérigo et al., 
2008) and the phenolic diterpene totarol 
(Smith et al., 2007) have been reported as 
EPIs against the SA-1199B strain. However, 
other factors, including special structural fea-
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tures may be crucial for the action of drugs 
on efflux pump inhibition. 
In fact, the lipophilicity of some sub-
stances, including alpha-tocopherol and cho-
lecalciferol can alter the structure of the bac-
terial lipoprotein membrane, resulting on 
damage to components that are essential for 
the membrane integrity, and therefore, efflux 
pumps and other membrane transporters may 
be significantly affected by these substances 
(Gibbons, 2004). The membrane potential 
can also be affected leading to loss of ions, 
cytochrome C, proteins and radicals and fi-
nally, collapse of proton pumps system and 
decrease in the intracellular ATP (Sikkema 
et al., 1994; Hirayama et al., 2006). 
Although the studies demonstrating the 
effect of the combination of antibiotics whit 
cholecalciferol remain to be developed, a re-
cent study demonstrated the effect of this 
substance as a modulator of the inflammato-
ry response on bovine mammary epithelial 
cells (Alva-Murillo et al., 2014). Interesting-
ly, prior to the development of the antibiot-
ics, sunlight (a source of vitamin D), cod liv-
er oil, and pharmacologic doses of liposolu-
ble vitamin D were used to treat tuberculosis 
(Martineau et al., 2007). This type of treat-
ment fell out of favor following the creation 
of effective antibiotic therapy. However, the 
interest in using pharmacologic doses of vit-
amin D increased recently in view of the 
finding that this vitamin can stimulate innate 
immune responses to combat several patho-
genic infections in vitro. Thus, vitamin D 
can act as an "antibiotic", in part, by induc-
ing the transcription of human antimicrobial 
peptide genes (Liu et al., 2006; Gombart et 
al., 2005; Zasloff, 2006). By this way, the 
potential use of cholecalciferol in association 
with antibiotics can represent an important 
weapon in the war against the MDR bacteria. 
 
CONCLUSION 
Cholecalciferal and alpha-tocopherol 
presented different patterns of antibiotic 
modulatory activity. Cholecalciferol present-
ed a significant modulatory effect on the tet-
racycline activity against the IS-58 S. aureus 
strain, indicating that this vitamin enhanced 
the antibiotic activity by affecting the bacte-
rial of efflux systems. Together, our data 
suggest that the vitamins act through specific 
mechanisms that are dependent on the bacte-
rial strain and the vitamin molecular struc-
ture and therefore, cholecalciferol can be 
used in the development of new drugs to 
treat infections caused by S. aureus resistant 
strains. 
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